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Aim. Determination of deletion of the long arm of chromosome 13 in the patients with chronic lympho-
cytic leukemia, diffuse large B-cell lymphoma and multiple myeloma to provide prognostic assessments 
of Chronic Lymphoproliferative Neoplasms (CLPN) sub-variants progression, and early detection of 
therapy resistant cases and relapses of CLPN. Methods. Preparations of bone marrow cells from all pa-
tients (n = 115) with CLPN were studied. Fluorescence in situ hybridization was performed using com-
mercial test Vysis LSI D13S319 (13q14.3) Spectrum Orange/ Vysis LSI 13q34 Spectrum Green FISH 
probe kit (Abbott Molecular, USA). Results. The molecular cytogenetic investigations have revealed 
deletions of 13q in 38 % of the patients with CLPN. We also present a clinical case where the deletion of 
13q is detected along with other cytogenetic aberrations that signifi cantly impair a disease prognosis. 
Conclusion. The analysis of deletions of the long arm of chromosome 13 is an important diagnostic and 
prognostic criterion, which assists to optimizes the treatment of the patients with CLPN.
K e y w o r d s: chronic lymphoproliferative neoplasms, chronic lymphocytic leukemia, multiple myelo-
ma, diffuse large B-cell lymphoma, 13q deletions, fl uorescence in situ hybridization.
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Introduction
Chromosomal abnormalities identifi ed by fl uorescence in 
situ hybridization (FISH) are known as prognostic factors 
for chronic lymphoproliferative neoplasms (CLPN) [1]. 
Among chromosomal abnormalities, deletion of the long 
arm of chromosome 13 (13q) is detected in more than 50 
% of cases of chro nic lymphocytic leukemia (CLL) [2] as 
well as in other B-cell malignancies [3], including de novo 
and transformed diffuse large B-cell lymphomas (DLB-
CL) [4, 5] and multiple myeloma (MM) [6].
Deletion of 13q is the most common cytogenetic ab-
normality in CLL [2]. This deletion represents early 
clonal aberration and suggests the loss of a tumor sup-
pressor gene. The loss or inactivation of the tumor sup-
pressor gene may be crucial for the development of 
CLL [7]. Deletion of 13q as a single aberration is as-
sociated with a good prognosis but additional abnor-
malities neutralize this favorable effect in CLL [8].
DLBCL has heterogeneous biological and clinico-
pathological characteristics. 30 % of non-Hodgkin’s 
lymphomas (NHL) and more than 80 % of aggres-
sive lymphomas are presented by DLBCL [9]. The 
aberrations of chromosome 13q are shown in differ-
ent NHLs including both indolent and aggressive B-
NHLs. The data suggest that the loss of genetic ma-
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terial of the chromosome band 13q14 may play an 
important role in the formation or development of a 
wide variety of mature lymphoid malignancies [10].
Multiple myeloma (MM) is a type of cancer for-
med by malignant plasma cells which show a com-
plex of cytogenetic and molecular genetic abnormal-
ities that not only essentially contribute to the patho-
genesis of this disease but also refl ect its prognostic 
heterogeneity [11, 12]. The aberrations of chromoso-
me 13 are found in approximately 50 % of cases [13]. 
They are associated with aggressive clinical condi-
tion, especially in combination with other genetic 
ab normalities. The recent studies suggest a crucial 
role of chromosome 13 deletions as a prerequisite 
for the clonal expansion of myeloma cells [14, 15].
Our study was designed to evaluate the prevalence 
of deletion of the long arm of chromosome 13 in the 
patients with B-CLL, DLBCL and MM to provide 
prognostic assessments of the CLPN sub-variants 
progression, and the early detection of therapy resis-
tant cases and relapses of CLPN.
Materials and Methods
Patients. 115 patients were included in the research: 
30 patients with diffuse large B-cell lymphoma (DL-
BCL), 25 patients with B-cell chronic lymphocytic 
leu kemia (B-CLL) and 60 patients with multiple 
mye loma (MM). All cases were diagnosed accord-
ing to 2008 World Health Organization (Classifi ca-
tion of Lymphoid Neoplasms) criteria [16]. The age 
of patients at diagnosis ranged from 5 to 79 years 
(the median is 59 years ). Three patients with DLB-
CL were children of 5, 10 and 11 years old. An aver-
age age for the patients with B-CLL was 59.60 ± 
± 2.69, for the patients with DLBCL – 47.30 ± 3.61, 
and 59.27 ± 1.03 for patients with MM. An average 
age of the patients with CLPN was 56.22 ± 1.31 
years, among them 13 (11.3 %) were younger than 
40 years. The substrate cells samples were obtained 
from 58 male and 57 female patients. The patients 
were informed about study objective and methods. 
Every patient has signed the informed consent.
Sample preparation and molecular cytogenetic 
stu dies. The research on cytogenetic abnormalities 
was performed on the 24-hour non-stimulated cul-
tures of bone marrow cells. The cultivation of native 
bone marrow (0.5 ml) for 24 hours was performed in 
5 ml culture medium RPMI-1640 («Sigma», USA) 
supplemented with 20 % fetal calf serum («Sigma», 
USA) and 20 ml of colchicines («Sigma», USA) for 
2h before fi xation. The cell suspension was incubat-
ed in a thermostat at 37 °C for 24 h. Upon comple-
tion of the cultivation, the hypotonic treatment of 
cells was carried out with heated up to 38 °C and pre-
pared ex tempore 0.075 M solution of potassium chlo-
ride for 20 min at 37 °C (1 ml of hypotonic solution to 
a precipitate obtained from 1 ml of culture). 8 ml of 
cooled holder (a mixture of methanol and glacial ace-
tic acid in a ratio of 3:1) was added to the cell suspen-
sion. The samples were left at + 4 °C for 15 min. Re-
placement of clamp was performed three times.
Fluorescence in situ hybridization. FISH was per-
formed on the samples from all patients (n = 115) 
with the Vysis LSI D13S319 (13q14.3) Spectrum 
Orange/ Vysis LSI 13q34 Spectrum Green FISH 
probe kit (Abbott Molecular, USA) according to the 
manufacturer’s protocol. The slides (prepared from 
the 24-hour non-stimulated culture) and probes were 
codenatured at 75 °C with Vysis Hybrite and hybrid-
ized at 37 °C for 16 hours. In each case, at least 200 
interphase nuclei with clear signals were analysed. 
To determine the normal range for the test Vysis 
LSI D13S319 (13q14.3) Spectrum Orange/ Vysis 
LSI 13q34 Spectrum Green FISH probe kit at least 
2000 interphase nucleus and 1000 metaphases of pe-
ripheral blood lymphocytes and bone marrow cells 
of ten healthy people of 16 to 67 years old (the aver-
age is 48.20 ± 4.88) were analysed. No 13q deletion 
was found in the nuclei from apparently healthy do-
nors (Fig. 1).
Cutoff levels for LSI D13S319/13q34 probe ran ged 
5 % based on scoring of peripheral blood and bone mar-
row controls. Analysis was performed on the software 
and hardware complex CytoVision (Applied Imaging, 
UK) based on microscope Olympus BX51, Japan.
Statistical analysis. Statistical analysis of the re-
sults was performed using Statistica 6.0 and Micro-
soft Offi ce Excel 2007. Signifi cance of differences 
between groups, which were analysed, was assessed 
using χ2 criterion and the Fisher criterion point rec-
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ommended for the small group size. The difference 
was considered as statistically signifi cant at p < 0.05. 
Determined parameters: mean, standard deviation, 
mean error and measurement error, minimum, maxi-
mum and median values, the maximum level of cells 
with abnormal set of signals [17, 18]. 
Results
Specifi c genomic abnormalities, such as loss of the 
13q14 and 13q34 regions, provide clinically signifi -
cant prognostic information. They are known to be 
associated with prognostic impact in CLPN patients, 
which is important for appropriate choice of thera-
peutic protocol. 
In the present study, we describe the frequency of 
deletions involving D13S319(13q14)/13q34 detected 
by FISH analysis in 115 patients with CLPN. Among 
the tested patients, 71 (61.74 %) had normal results, 
while 44 (38.26 %) had at least one genetic aberration. 
The analysis of interphase nuclei of bone marrow cells 
from the patients with CLPN showed that a single 
anomaly was registered in 30 (68.18 %) patients, and 
coexistence of two aberrations was revealed in 14 
(31.82 %) ones. The FISH results are given in Table 1.
Fig. 2. The results of FISH on interphase nucleus of bone marrow cells of patient P. using LSI 
D13S319/13q34 Probe kit. Most of analysed cells showed one red (13q14.3) and two green 
(13q34) signals that corresponds to deletions of chromosome 13 in the region 13q14.3
Fig. 1. The results of FISH on interphase nucleus and metaphases of peripheral blood lymphocytes and bone marrow cells of healthy 
donors using LSI D13S319/13q34 Probe kit. Two red (chromosome 13q14.3) and two green (chromosome 13q34) signals were 
registered in the normal cell nuclei
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In molecular cytogenetic study of bone marrow 
cells of the patients with B-CLL for each sample from 
200 to 300 interphase nuclei were analysed, the total 
number of nuclei was 5640 (in average, 225.60 ± 
± 8.11), among them 5180 (91.84 %) of nuclei (in 
average, 207.20 ± 11.20) were with normal distribu-
tion of signals 2Ox2G (D13S319, Spectrum Orange 
x 13q34, Spectrum Green). According to the results, 
the percentage of abnormal cells in average was 9.12 ± 
± 2.2. The number of nuclei with deletion of D13S319 
varied in the range of 8 – 94 with the average of 
13.68 ± 4.31, the percentage of abnormal cells was 
6.84 ± 2.16. The signals (1O), which characterize the 
gene D13S319 deletion, were determined in ten pa-
tients with B-CLL. In 100 nuclei (1.77 % of the total 
number of analysed cells), an abnormal distribution 
of signals (1G) was determined. Thus, in fi ve of 25 
patients (20 %), the presence of 13q34 deletion has 
been found. Among 25 cases in the group with coex-
istence of two aberrations, three cases (12 %) had two 
aberrations. One of the patients had polysomy of chro-
mosome 13 in 60 out of 200 analysed nuclei (30 %).
30 samples from the patients suffering from DL-
BCL were studied. A normal pattern of signals (2Ox 
2G) was registered in 6332 (in average, 211.07 ± 
± 9.72) cells, presenting 93.39 %. In 374 nuclei 
(5.52 % of the total number of analysed cells) an ab-
normal distribution of signals was determined. Over-
all, the aberrations of chromosome 13 were detected 
in 12 out of 30 (40 %) samples from the patients with 
DLBCL. Based on the interphase FISH analysis, six 
patients had D13S319 deletion; three of these pa-
tients had D13S319 deletion as a single abnormality, 
and three patients had additional delition (13q34). 
Thus, in eight out of 30 patients (26.67 %) Green 
hybridization signal was determined, indicating the 
presence of 13q34 deletions. The number of nuclei 
with 13q34 deletion varied in the range from 16 to 
60 with the average of 9.20 ± 3.04. Therefore, the 
percentage of abnormal cells was 4.60 ± 1.52. One 
of the patients had also trisomy in 40 out of 200 anal-
ysed nuclei (20 %) and the other one had polysomy 
in 50 out of 300 cells (25 %).
We have evaluated 60 samples from the patients 
with MM. The interphase nuclei were analysed, a to-
tal amount of nuclei was 14170 (in average 236.17 ± 
± 7.05), among them 12999 (91.74%) in average 
216.65 ± 9.45 with a normal distribution of thr sig-
nals (2Ox2G). 19 patients (31.67%) had at least one 
genetic abnormality. Accordingly, the percentage of 
abnormal cells in average was 8.64 ± 2.24. 11 pati-
ents (57.89 %) had one abnormality; eight (42.11 %) 
had two abnormalities. The results showed the 
D13S319 deletion in 13 patients, abnormal distribu-
Table 1. 13q deletions in bone marrow cells in the patients with B-CLL, MM, DLBCL and BL
No. Literature Country Diagnosis Tested patients 13q deletion, n
1 Chang et al. [19] Korean B-CLL 16 9
2 Eid et al. [7] Egypt B-CLL 20 16
3 Degheidy et al. [20] USA B-CLL 54 33
4 Own data Ukraine B-CLL 25 12
5 Caraway et al. [21] Texas DLBCL 11 7
6 Nelson et al. [5] Nebraska BL 90 38
7 Havelange et al. [22] Belgium
France
BL
DLBCL
BL/DLBCL
37
12
28
15
6
5
8 Own data Ukraine DLBCL, BL 30 10
9 Durak et al. [23] Turkey MM 50 27
10 Gao et al. [12] China MM 60 38
11 Oh et al. [15] Korea MM 929 218
12 Own data Ukraine MM 60 18
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tion of the signals (1O) was determined in 907 nuclei 
(6.40 % of all analysed cells). The 13q34 abnormal-
ity was observed in 13 out of 60 cases (21.67%). Po ly-
somy of chromosome 13 was present in one patient.
Description of individual clinical case
Patient P. (female), born in 1969, medical history N 
6411, was examined in the Department of Radiation 
Heamatology of SI «National Scientifi c Center for 
Radiation Medicine of NAMS of Ukraine» in Au-
gust 2004. Moderate leukocytosis and lymphocyto-
sis were revealed in peripheral blood. The patient 
was observed by a haematologists and was exam-
ined for the second time in the Department of Radia-
tion Medicine in May 2007. The test of peripheral 
blood cells from 07.05.2007 showed an increased 
number of white blood cells (CD 45+ – 91 %, CD 
19+ – 91 %, CD 20+ – 41 %, CD 22+ – 91 %, CD 11c+ – 
53 %, CD 5+ – 55 %). Based on the clinical hemato-
logical data and assessment of the patient immune sta-
tus, B-cell chronic lymphocytic leukemia was diag-
nosed. The patient was treated with Leukeran (Chloram-
bucil) 10 mg daily, two cycles from 23-May-2005 to 
07-Jun-2007 and from 27-Jul-2007 to 05-Aug-2007 (a 
total dose of chlorambucil was 260 mg) with short-
lasting effect. The second line therapy was performed 
from 24-Dec-2007 to 25-Jun-2008, exactly, 6 cycles of 
chemotherapy according to FluCam protocol: Fludara-
bine 45 mg/m2 intravenous (IV) from the fi rst to the 
third day, Campath 30 mg/m2 IV from the fi rst to the 
third day. The complete hematologic remission was 
achieved. The third line therapy was performed from 
30-Apr-2010 to 20-Jul-2010; 3 cycles of chemotherapy 
according to COP regimen: Vincristine 2 mg IV in the 
fi rst day, Cyclophosphamide 400 mg IV from the fi rst 
to the fi fth day, Methylprednisolone 64 mg IV orally 
from the fi rst to the fi fth day, a complete disease stabi-
lization was achieved. The forth line therapy was per-
formed from 20-Jul-2011 to 31-Dec-2011: 6 cycles 
of chemotherapy according to OFC regimen: Ofatu-
mumab 1000 mg IV in fi rst day, Fludarabine 22 mg 
IV in 1–3 days, Cyclophosphamide 220 mg IV in 1-3 
days, a partial remission was achieved. 
The disease progression and Fludarabine resistan-
ce were confi rmed for the patient on 23-Oct-2012. In 
April 2013, the samples of bone marrow cells were 
studied using interphase FISH in the Department of 
Hematology and Transplantology, SI «National Sci-
entifi c Center for Radiation Medicine of NAMS of 
Ukraine». The presence of deletions of chromosome 
13, namely, its regions 13q14.3 and 13q34, was stud-
ied using the samples hybridization with probe kit 
LSI D13S319 (13q14.3) Spectrum Orange / Vysis 
LSI 13q34 Spectrum Green (Abbott Molecular, 
USA). 200 interphase nuclei were analysed. Most 
(70 %) of analysed cells showed one red (13q14.3) 
signal and two green (13q34) signals, indicating the 
clonal nature of the tumor and the presence of dele-
tions of chromosome 13 in the region 13q14.3. Other 
nuclei (30 %) showed two red and two green signals 
that corresponds to norm.
As a result of study, del (13q) was found in 70 % of 
analysed cells. According to the literature, the chro-
mosome 13 deletion can be a positive prognostic 
mar ker in the patients with B-CLL if no related stru-
ctural aberrations and quantitative changes in other 
chromosomes were found. However, the FISH anal-
ysis revealed the following changes of chromosomes 
in the patient: gene TP 53 deletion – 47 % (chromo-
some 17), deletion of chromosome 11 (11q22.3) – 
39 %, hiperaneuployidy of chromosome 14 (mono-
somy – 20 % , trisomy – 8%), polyploidy of chromo-
some 16–18 %.
There were detected changes of chromosomes. The 
abnormalities of chromosomes 11, 13, 14, 16 and 17 
may indicate unfavourable prognosis for the patient P.
After our studies, the cytoreductive treatment of 
the patient was intensifi ed with administration of im-
munotherapy (monoclonal antibodies such as Ritux-
imab and Ibrutinib) in combination with chemother-
apy. Despite the intensifi ed treatment , the patient 
achieved only short-lasting effects and the diseases 
continued to progress. The diseases prognosis is un-
favourable.
Discussion
This study evaluated 115 CLPN patients with chro-
mosomal abnormalities via interphase FISH. The ge-
netic abnormalities at CLPN are typically complex 
and represent a hallmark of the disease, many chro-
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mosomes are impacted in both number and structure. 
The conventional cytogenetic methods detect abnor-
mal chromosomes approximately in 26–40 % of 
cases due to a low proliferative activity in vitro of 
B-cells, whereas FISH enables the detection of spe-
cifi c abnormalities in up to 86–98 % of the cases [24, 
25]. The results of our research and the similar data 
of other authors are presented in Table 1.
In FISH analysis of the patients observed, the de-
letions of 13q are detected in almost 35 % of CLPN 
cases. Thus, the chromosome 13 deletions were fo-
und in 12 out of 25 patients with B-CLL, 10 out of 
30 patients with DLBCL and 18 out of 60 patients 
with MM. The average percentage of deletion of 13q 
for the patients with CLPN was respectively 48 %, 
33 % and 30 %, that was slightly lower than de-
scribed in the literature. In general, the results pre-
sented in Table 1 show a slight divergence between 
our data and results of other researchers. At the same 
time, among 60 patients with MM, the deletion in 
chromosome 13 was registered in 18 patients, which 
is signifi cantly lower than Gao et al. [12] showed, 
they identifi ed the deletion of 13q in 38 out of 60 
patients with MM. In our study, the deletion of 
D13S319 locus located in 13q14 was detected in 29 
out of 115 patients with del(13q), while the del(13q14) 
was determined in 26 out of 115 patients with CLPN. 
In the patients with B-CLL the deletion of 13q14 
was identifi ed in 10 out of 25 patients, while deletion 
of 13q34 was presented only in fi ve out of 25 pa-
tients. Conversely, testing 60 patients with MM 
showed the deletion of 13q in 18 patients: deletions 
of 13q14 and 13q34 were identifi ed in 13 analysed 
cases. In the patients with MM, the presence of dele-
tion of 13q is a poor prognostic factor, while it is 
related to good prognosis in B-CLL. 
Consequently, according to the analysed in detail 
research results, the following aspects are worth not-
ing. In the case of B-CLL patients, our data are com-
parable with those received by Chang et al. [19], 
though they refer to a smaller number of patients ex-
amined. A little higher percentage of the chromo-
some 13 abnormalities is shown in the researches of 
Degheidy et al. [20]. Perhaps, it is connected with 
the fact that in this work peripheral blood cells were 
studied, whereas in our study – bone marrow cells. 
The work of Eid et al. [7] showed a signifi cant num-
ber of the patients with the chromosome 13 aberra-
tions. However, in this work the FISH analyses were 
conducted following three chemotherapy courses. 
Our patients were examined to the background ther-
apy, at the initial examination. Accordingly, the FISH 
analysis was carried out at different stages of diag-
nostics and treatment.
As regards patients with the DLBCL, obviously, 
the distinctions are connected with a small group of 
examined patients: Caraway et al. [21] (11 patients – 
63 %) and Havelange et al. [22] (12 patients – 50 %). 
Nelson et al. [5] examined patients with Burkitt’s 
lymphoma, which in essence is an aggressive lym-
phoma among non-Hodgkin’s ones.
As for the MM patients, our data are consistent 
with the data received by Oh et al. [15], though a 
considerably larger number of patients were analy-
sed in their work. In the work of Gao et al. [12], the 
authors used purifi ed plasma cells, we identifi ed the 
plasma cells using the monoclonal antibodies. In the 
work of Durak et al. [23], the FISH analysis was car-
ried out on bone marrow cells with no plasma cell 
identifi cation. Therefore, considering this we and the 
authors of [12] were guided by recommendations of 
the European Myeloma Network in the abnormal 
cell counting, the differences in the frequency of 
chromosome 13 aberrations can be related to the use 
of different plasmocyte isolation methods.
Besides, we would like to notice that the differences 
may be of an ethnic nature as well since our work pre-
sented the data from various countries of the world.
Conclusion
The present study shows the signifi cance of identifi -
cation of differential diagnostic markers of the dis-
ease for patients with CLPN, in particular, the dele-
tion of critical regions 13q for optimizing the treat-
ment of patients. The further FISH studies, which 
will involve more patients with B-CLL, DLBCL and 
MM, are required to fi nd out a more comprehensive 
pattern of genetic changes in the long arm of chro-
mosome 13 for the diseases prognosis in the Ukrai-
nian patients with CLPN.
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Діагностичне і прогностичне значення
визначення 13q делецій за допомогою флуоресцентної
in situ гібридизації 
В. В. Сітько, Ж. А. Мішаріна, Ж. М. Мінченко,
Л. О. Полубень, О. О. Дмитренко, Ю. О. Сілаєв,
Н. І. Костюкова, О. В. Ткаченко, А. О. Товстоган,
В. М. Полянська, Л. О. Ляшенко, В. Г. Бебешко
Мета. Визначення делецій довгого плеча хромосоми 13 у 
хворих на хронічну лімфоцитарну лейкемію, дифузну круп-
ноклітинну В-лімфому і множинну мієлому для надання прог-
ностичних оцінок щодо перебігу цих підваріантів хроніч-
них лімфопроліферативних новоутворень (ХЛПН), та своє-
часного виявлення резистентних до терапії випадків і реци-
дивів ХЛПН. Методи. Досліджено 115 препаратів клітин 
кісткового мозку хворих на ХЛПН. Флуо ресцентну in situ гі-
бридизацію проводили з використанням комерційної про-
би Vysis LSI D13S319 (13q14.3) Spectrum Orange / Vysis LSI 
13q34 Spectrum Green FISH probe kit (Abbott Mo lecular, 
США). Результати. При молекулярно-цитоге не тич них до-
слідженнях наших пацієнтів, делеції 13q були виявлені в 
38 % випадків ХЛПН. Також, наведений опис клінічного 
випадку, де показано, що наявність делецій 13q разом з ін-
шими цитогенетическими абераціями значно погіршує 
прогноз захворювання. Висновки. Аналіз делецій довгого 
плеча хромосоми 13 є важливим діагностичним і прогнос-
тичним критерієм, який дозволить оптимізувати лікування 
хворим на ХЛПН.
Ключов і  слова: хронічні лімфопроліферативні новоут-
во рен ня, хронічна лімфоцитарна лейкемія, дифузна крупно-
клітинна В-лімфома, множинна мієлома, 13q делеція, флуо-
ресцентна in situ гібридизація.
Диагностическое и прогностическое значение
определения 13q делеций с помощью флуоресцентной
in situ гибридизации 
В. В. Ситько, Ж. А. Мишарина, Ж. Н. Минченко,
Л. А. Полубень, Е. А. Дмитренко, Ю. О. Силаев,
Н. И. Костюкова, О. В. Ткаченко, А. А. Товстоган,
В. М. Полянская, Л. А. Ляшенко, В. Г. Бебешко
Цель. Определение делеций длинного плеча хромосомы 13 
у больных с хронической лимфоцитарной лейкемией, диф-
фузной крупноклеточной В-лимфомой и множественной 
миеломой для прогностической оценки течения этих подва-
риантов хронических лимфопролиферативных новообразо-
ваний (ХЛПН), и своевременного выявления резистентных 
к терапии случаев и рецидивов ХЛПН. Методы. Исследова-
но 115 препаратов клеток костного мозга больных с ХЛПН. 
Флуоресцентную in situ гибридизацию проводили с исполь-
зованием коммерческой пробы Vysis LSI D13S319 (13q14.3) 
Spectrum Orange/ Vysis LSI 13q34 Spectrum Green FISH probe 
kit (Abbott Molecular, США). Результаты. При молекуляр-
но-цитогенетическом исследовании препаратов субстрат-
ных клеток наших пациентов, делеции 13q были обнаруже-
ны в 38 % случаев ХЛПН. Также, представлен клинический 
случай, где показано, что наличие делеций 13q вместе с дру-
гими цитогенетическими аберрациями значительно ухуд-
шает прогноз заболевания. Выводы. Анализ делеций длин-
ного плеча хромосомы 13 является важным диагностичес-
ким и прогностическим критерием, который позволит опти-
мизировать лечение больным на ХЛПН.
Ключевые  слова: хронические лимфопролифератив ные 
новообразования, хроническая лимфоцитарная лейкемия, диф-
фузная крупноклеточная В-лимфома, множественная миелома, 
13q делеция, флуоресцентная in situ гибридизация.
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